These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
    Author: Oda K.
    Journal: Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091.
    Abstract:
    The Ras-PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian Target of Rapamycin) pathway is frequently activated in various types of cancers. A number of inhibitors targeting the PI3K/mTOR pathway and MAPK pathway (another Ras effector pathway) are under development. PI3K/AKT activating mutations, including mutations in PTEN (50%), PIK3CA (30%), and K-Ras (20%), are frequently observed in endometrial cancer. A coexistence of these mutations is also commonly observed. We classified 13 endometrial cancer cell lines into three groups according to their mutational status in these genes: Group A (n=9); K-Ras wild-type and PTEN mutant, Group B (n=2); K-Ras mutant, and Group C (n=2) without any mutations in K-Ras, PTEN or PIK3CA. We determined the effects a dual PI3K/mTOR inhibitor (Inhibitor P) on these cell lines. MTT assay revealed that all the nine cell lines in Group A were sensitive to the inhibitor P (IC50<100 nM), whereas the other four cell lines in Group B or C were less sensitive to it(IC50>100 nM). Daily oral administration of inhibitor P showed anti-tumor effects in the mice bearing Group A tumors. Our data suggest that dual inhibition of the PI3K/mTOR is a promising molecular-targeted therapeutic for certain endometrial cancers, and that the mutational status of K-Ras and PI3K pathway-related genes, like PTEN and PIK3CA, could be useful for predicting sensitivities to such agents.
    [Abstract] [Full Text] [Related] [New Search]